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Cervical cancer is one of the most common malignancies occurring
during pregnancy with approximately 3% of all new cases diagnosed
during this time (Nguyen et al., 2000). Accounting for only 2% of cervical
malignancies, neuroendocrine carcinoma is a rare entity in the general
population, disregarding the gravid (Gardner et al., 2011). The clinical
course of neuroendocrine carcinomahas historically been dismal with a
propensity for early metastasis and lymph node spread at early stages
and a median survival of only 22 months (Chen et al., 2008; McCusker
et al., 2003). Treatment of this rare malignancy has evolved as a hybrid
from the experiences with squamous cell carcinoma of the cervix and
neuroendocrine carcinoma of the lung. A comprehensive review by
Gardner et al. (2011) has provided us with recommendations focused
on radical excision and adjuvant chemotherapy for early stage disease.
With only 15 cases published since 1976, there is no consensus of
neuroendocrine carcinoma of the cervix during pregnancy. Thus, the
management in this circumstance must be individualized. We present
our experience with a patient diagnosed with neuroendocrine carcino-
ma of the cervix in the 1st trimester of pregnancy who refused
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A 31-year-old Caucasian woman, gravida 2, para 1, was referred to
our institution for newly diagnosed neuroendocrine cancer of the cervix
at 10 weeks gestation. She initially presented to her primary obstetri-
cian, without complaints, to re-establish obstetrical care. Her screening
pap returned abnormal resulting in a colposcopy with cervical biopsies.
Biopsy pathology resulted in a poorly differentiated neuroendocrine
cancer of the uterine cervix. The patient was then referred to our
institution where review by our departmental gynecopathologist
conﬁrmed the diagnosis.
The patient was staged as FIGO grade 1B1 after physical exam
revealed a 1-cm friable lesion on the posterior lip of the cervix. She was
extensively counseled about the aggressive nature of her tumor and
was advised to undergo radical hysterectomy followed by adjuvant
chemotherapy. The patient refused any intervention that would result
in fetal demise and desired to maintain her pregnancy as close to term
as possible. For this reason, preoperative imagingwas not obtained, as it
would not alter the treatment plan. At 13 weeks gestation she agreed to
undergo therapeutic cervical conization with simultaneous placement
of a McDonald cerclage. Cervical cone pathology revealed poorly
differentiated neuroendocrine carcinoma with focal small cell compo-
nent and endocervical adenocarcinoma in situ. The neuroendocrine
carcinoma cells showed immunoreactivity with CEA, CD-56, chromo-
granin, synaptophysin, and P-16. The adenocarcinoma in situ compo-
nent showed immunoreactivity with CEA and P-16. No uptakewas seen
with CD-56, chromogranin, or synaptophysin. Outside pathologic
review was not performed. Although margins were negative for
neuroendocrine carcinoma, the pathologist reported the specimen to
be fragmented and could not ensure complete excision.
The patient was once again offered deﬁnitive therapy; however, she
remained adamant about preserving the pregnancy. She was then
offered and agreed to adjuvant chemotherapy. Her regimen included
cisplatin (75 mg/m2, intravenously, on day 1) and etoposide (100 mg/
m2 on days 1, 2, and 3) over a 21-day cycle. She received a total of four
courses at approximately 17, 20, 23, and 26 weeks gestation. The
patient tolerated chemotherapy without side effects and fetal surveil-
lance showed appropriate growth throughout the pregnancy.
Timing of delivery was decided between the obstetrician and
perinatologist. A balance between delivery before the onset of labor
and the risk of neonatal respiratory distress syndrome guided their
decision. As the patient's previous pregnancy resulted in spontaneous
labor at 37 weeks gestation, the decision was made to deliver at
36 weeks. The risk for immature fetal lungs was thought to be further
reduced by the maternal administration of systemic steroids as a
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performed. The patient delivered by cesarean section resulting in a
2806 g (37th percentile) newborn. After delivery of the fetus, the
team proceeded with a radical hysterectomy, bilateral salpingo-
oophorectomy, and pelvic lymph node dissection. Pathology was
negative for residual disease and 22 lymph nodes were negative for
malignancy. The patient has been without evidence of the disease
24 months later. Her child shows no physical effects of the maternal
chemotherapy and is meeting all developmental milestones.
Discussion
Neuroendocrine carcinoma of the cervix is a rare malignancy that
has an aggressive clinical course and reduced survival when compared
to the more common histological subtypes (squamous cell and
adenocarcinoma) (Chen et al., 2008). In 2011, guidelines for the
management of this condition were created and are centered around
a multimodality approach (Gardner et al., 2011). Considerations for
treatment during pregnancy include the maternal desire to potentially
preserve the pregnancy and the impact of treatment on fetalwell-being.
Our case presents several unique factors: 1. First trimester diagnosis
with prolonged delay in deﬁnitivemanagement, 2. Therapeutic excision
of stage 1B1 tumor via cold knife conization, 3. Use of etoposide/
cisplatinum during pregnancy.
General principles for the management of cervical cancer during
pregnancy are based on gestational age, maternal desire to continue
pregnancy, and stage. At previable gestational ages, the mother is
traditionally offered deﬁnitive management (Van Calsteren et al.,
2005). Women diagnosed with neuroendocrine carcinoma of the
cervix during pregnancy have historically been offered deﬁnitive
therapy regardless of gestational age and expectant management
should be highly discouraged. Our patient was the ﬁrst to be
diagnosed in the 1st trimester that declined deﬁnitive treatment.
In an effort to excise the primary lesion without interrupting the
pregnancy, our patient was offered a therapeutic cervical conization.
Cervical conization is generally indicated during pregnancy to rule out
invasive disease or treat micro invasive (1A1) disease. This is not
recommended as a therapeutic option during pregnancy, as the
modiﬁcation of obtaining a more ﬂat, broad specimen can result in
residual disease with positive margins (Hannigan et al., 1984). The
optimal time to perform this procedure is between 14 and 20 weeks
gestation (Van Calsteren et al., 2005). This minimizes the 1st trimester
risk of miscarriage and the increasing risk of severe hemorrhage and
preterm laborwith advancing gestational age.When amore traditional,
or aggressive conization is performed, simultaneous placement of a
cerclage is a feasible and safe option (Goldberg et al., 1991).
Upon review of the cervical cone specimen, our pathologist was
unable to conﬁdently report that the entire neuroendocrine component
was excised. After a department wide discussion reached a consensus,
the patient was once again advised to proceed with deﬁnitive radical
hysterectomy with fetus in situ, or chemotherapy as an alternative,
based on maternal wishes. The patient opted for chemotherapy.Several review articles suggest that the administration of chemo-
therapy during pregnancy should be avoided during the 1st trimester
(organogenesis) and that 2nd and 3rd trimester use appears to be safe
(Mir et al., 2008; Cardonick and Iacobucci, 2004). The patient was
administered etoposide and cisplatin (EP) as there was insufﬁcient
evidence to suggest this regimen would put the fetus at undue risk.
Neuroendocrine carcinoma of the cervix is a rare malignancy,
with our patient being the 16th reported case to occur during
pregnancy. As this subtype of cervical cancer is characterized by an
aggressive clinical course, deﬁnitive management should be offered
regardless of gestational age. Although experience in the pregnant
population is limited, the rapid administration of a multimodality
treatment plan resulting in improved progression free and overall
survival has been demonstrated (Gardner et al., 2011). In women
who desire pregnancy preservation, treatment that provides an
acceptable balance between maternal survival beneﬁt and fetal/
pregnancy risks should be initiated. By following the principles
established by Gardner et al., we report an alternative approach to
the management of early stage neuroendocrine carcinoma of the
cervix during pregnancy. We performed a therapeutic cone cerclage
for a stage 1B1 lesion followed by the administration of multi-agent
chemotherapy. Final pathology from the radical hysterectomy and
lymphadenectomy showed no evidence of residual or metastatic
disease. We believe that the therapeutic cone optimized the
maternal beneﬁt while allowing pregnancy preservation.Conﬂict of interest statement
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